Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04624204
Title Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung small cell carcinoma

Therapies

Pembrolizumab

Cisplatin + Etoposide

Cisplatin + Etoposide + Pembrolizumab

Carboplatin + Etoposide

Olaparib + Pembrolizumab

Carboplatin + Etoposide + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL


No variant requirements are available.